Olema Pharmaceuticals, Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
OLMA Nasdaq 2830 olema.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Olema Pharmaceuticals, Inc.

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Nov 4th, 2025 2:30 pm
Olema Oncology to Participate in Upcoming Investor Conferences - Nov 3rd, 2025 2:30 pm
Olema Oncology to Present Trial-in-Progress Poster for Phase 3 OPERA-02 Trial of Palazestrant Plus Ribociclib at SABCS 2025 - Oct 30th, 2025 2:30 pm
Olema Pharmaceuticals Shares Fall After Roche's Breast Cancer Data Weighs on Sector - Oct 20th, 2025 9:25 am
Wall Street Set to Open Higher Monday as Investors Look Ahead to a Week of Earnings Reports - Oct 20th, 2025 7:27 am
Investors Look Ahead to Key Earnings Reports as US Futures Rise Monday Pre-Bell - Oct 20th, 2025 6:01 am
Olema Oncology Announces New Data from the Phase 1b/2 Trial of Palazestrant Plus Ribociclib in ER+/HER2- Metastatic Breast Cancer at ESMO 2025 - Oct 18th, 2025 1:00 am
Guggenheim Initiates Olema Pharmaceuticals (OLMA) Coverage with Buy Rating and $20 PT, Cites Palazestrant Potential - Oct 16th, 2025 2:33 pm
Goldman Sachs Raises Stake in Olema Pharmaceuticals, Inc. (OLMA) - Sep 30th, 2025 9:41 am
OLMA Stock Soars 47% in September So Far on Second PFE Deal - Sep 12th, 2025 8:38 am
Pfizer Inc (PFE) Announces New Trial Collaboration With Olema Pharmaceuticals - Sep 7th, 2025 8:23 am
Pfizer (PFE) Partners With Olema For New Metastatic Breast Cancer Study - Sep 3rd, 2025 11:25 am
Olema Oncology Announces New Clinical Trial Agreement with Pfizer to Combine Palazestrant with Atirmociclib in ER+/HER2- Metastatic Breast Cancer - Sep 2nd, 2025 5:00 am
Clinical Trial Progress and Analyst Endorsement Spark Short-Term Rebound for Olema Pharmaceuticals - Aug 12th, 2025 11:15 pm
Olema Oncology Reports Second Quarter 2025 Financial and Operating Results - Aug 11th, 2025 2:01 pm
Olema Oncology Announces Palazestrant Dose Selection and Trial-in-Progress Poster at ASCO 2025 Annual Meeting - May 28th, 2025 5:00 am
Wall Street Analysts See a 386.42% Upside in Olema Pharmaceuticals (OLMA): Can the Stock Really Move This High? - May 21st, 2025 7:55 am
Companies Like Olema Pharmaceuticals (NASDAQ:OLMA) Are In A Position To Invest In Growth - May 15th, 2025 5:47 am
Olema Oncology Reports First Quarter 2025 Financial and Operating Results - May 13th, 2025 2:01 pm
Olema Pharmaceuticals Says OP-3136 Molecule Shows Anti-Tumor Activity in Preclinical Models - Apr 25th, 2025 11:32 am